A tablet of clopidogrel remaining in the lower esophagus after primary percutaneous coronary intervention for acute myocardial infarction

A 70-year-old woman with ST-segment elevation myocardial infarction (STEMI) underwent primary percutaneous coronary intervention (pPCI). She did not have a past history of either gastrointestinal disease or pemphigoid. Before the pPCI, she received dual antiplatelet therapy (a total of six tablets taken as a loading dose without much water) and maintained a supine position for several hours. The patient experienced back pain during the pPCI procedure, and blood testing showed a hemoglobin level of 10.0 g/dL. During gastroscopy after the pPCI, a thin white coat of esophageal erosion was noted (Fig. 1 a, b), and a clopidogrel tablet (red arrow) was seen remaining in the esophagus (Fig. 1 c). A clopidogrel tablet remained in the esophagus. A gastroscopic image obtained 1 week after pPCI shows healing of the epithelial membrane.

A 70-year-old woman with ST-segment elevation myocardial infarction (STEMI) underwent primary percutaneous coronary intervention (pPCI). She did not have a past history of either gastrointestinal disease or pemphigoid. Before the pPCI, she received dual antiplatelet therapy (a total of six tablets taken as a loading dose without much water) and maintained a supine position for several hours. The patient experienced back pain during the pPCI procedure, and blood testing showed a hemoglobin level of 10.0 g/dL. During gastroscopy after the pPCI, a thin white coat of esophageal erosion was noted (Fig. 1 a, b), and a clopidogrel tablet was seen remaining in the lower esophagus (Fig. 1 c). The fiberoscope could not be advanced to the stomach because the erosion extended to the lower esophagus with narrowing. Neither a hematoma at the vascular access site nor a retroperitoneal hematoma was observed by computed tomography, and no malignancy was diagnosed.

The antplatelet therapy was discontinued, and the patient was treated with an intravenous high calorie diet and proton pump inhibitor for 1 week. A second gastroscopy showed healing of the esophageal epithelial membrane (Fig. 1 d) and no evidence of gastric ulcer. No stent thrombosis occurred during the recovery period, and she resumed her daily intake of 100 mg of aspirin.

It is not clear if the drug itself caused the widespread exfoliation of the lower esophageal mucosa seen in this patient. Another possibility is that the exfoliation resulted from ischemic mucosal damage or “stress” associated with STEMI, and the drug exacerbated the problem to some extent. Because clopidogrel is a prodrug and exerts its antplatelet effect after absorption, the clopidogrel tablet itself probably stimulated the esophageal mucosa in the present case [1 – 3].

To avoid such undesirable situations, a patient with STEMI who is undergoing pPCI should take an adequate amount of water with the pills and should maintain a right lateral decubitus position for a few minutes in the emergency room before going to the catheter laboratory.

Endoscopy_UCTN_Code_CCL_1AB_2AC_3AD

Competing interests:
None

Tomomi Koizumi, Shigeyuki Nishimura
Department of Cardiovascular Medicine, Saitama International Medical Center, Saitama Medical University, Hidaka, Japan

Acknowledgement
The authors wish to thank Heidi N. Bonneau, RN, MS, CCA, and Hideaki Kaneda, MD, PhD, for their expert review of this report.

References

Bibliography
DOI http://dx.doi.org/10.1055/s-0034-1393231
Endoscopy 2015; 47: E508
© Georg Thieme Verlag KG Stuttgart · New York ISSN 0013-726X

Corresponding author
Tomomi Koizumi, MD
Division of Cardiovascular Medicine Saitama International Medical Center Saitama Medical University 1397-1 Yamane Hidaka Saitama 350-1298 Japan Fax: +81-42-984-4741 tkoizumi@saitama-med.ac.jp

Koizumi Tomomi, Nishimura Shigeyuki. Clopidogrel tablet remaining in the lower esophagus after pPCI... Endoscopy 2015; 47: E508